SOUTH BRUNSWICK TOWNSHIP, N.J., Nov. 12, 2026 /PRNewswire/ -- TheWell Bioscience, a developer of an integrated animal origin-free 3D cell culture platform, announced the launch of RocketCell™ S1, S2, and S3 Supplements, AOF, a new portfolio of animal origin-free supplements designed to support reproducible and scalable stem cell, neural, organoid, and other advanced cell culture applications.

The portfolio includes RocketCell™ S1 Supplement (B27-like), RocketCell™ S2 Supplement (N2-like), and RocketCell™ S3 Supplement (N2B27-like premix). The launch expands the company's end-to-end animal origin-free (AOF) portfolio, giving researchers additional tools to build human-relevant cell culture platforms for New Approach Methodologies (NAMs) and other advanced research applications.

Explore RocketCell™ Animal Origin-Free B27-Like, N2-Like, and N2B27-Like Supplements.

"Our goal is to help human-relevant platforms move beyond the research lab and ultimately toward GMP production and clinical translation," said John Huang, Ph.D., CEO of TheWell Bioscience. "RocketCell™ S1, S2, and S3 strengthen the animal origin-free tools available to researchers today. By synthetic hydrogels, integrating media, recombinant growth factors, cultureware, and workflow reagents, our end-to-end AOF platform supports the development of more standardized and reproducible human-relevant models for NAMs. This integrated approach also supports our long-term strategy to develop GMP-grade solutions for future biomanufacturing and clinical applications."

Reducing animal-origin components helps researchers better control culture inputs and minimize biological variability. RocketCell™ S1, S2, and S3 provide animal origin-free alternatives to conventional N2- and B27-type supplements for advanced cell culture workflows.

The supplements complement TheWell Bioscience's expanding AOF ecosystem, including RocketCell™ media, VitroGel® synthetic hydrogels, CytoGrow™ recombinant growth factors, VitroPrime™ cultureware, and Cyto3D® workflow reagents. Together, these solutions support an integrated workflow from cell expansion through organoid development, helping researchers build more complete AOF workflows for human-relevant research and NAMs.

RocketCell™ S1, S2, and S3 Supplements are currently intended for Research Use Only (RUO). TheWell Bioscience plans to develop GMP-grade versions as part of its broader strategy to support the progression of human-relevant cell culture platforms from research toward biomanufacturing and clinical translation.

About TheWell Bioscience Inc.
TheWell Bioscience is a biotechnology company delivering an end-to-end animal origin-free portfolio for reproducible 3D cell models. Its integrated ecosystem includes VitroGel® hydrogels, RocketCell™ media and supplements, VitroPrime™ cultureware, CytoGrow™ growth factors, and Cyto3D® reagents. By reducing animal-derived variability, the company provides scalable solutions supporting organoid research, precision medicine, cell therapy, biomanufacturing, and New Approach Methodologies (NAMs).

Contact:
Kyra Baricaya
9738554955
426865@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/thewell-bioscience-launches-rocketcell-aof-b27-like-n2-like-and-n2b27-like-supplements-advancing-nams-and-future-gmp-development-302937379.html

SOURCE TheWell Bioscience